Overview
Infective encephalitis involves inflammation of the brain parenchyma due to infection, often viral, leading to neurological symptoms and potential life-threatening complications 1.Diagnosis
Clinical Presentation: Fever, altered mental status, focal neurological deficits 1.
CSF Analysis: Elevated white blood cells, protein, and often low glucose levels 1.
Imaging: MRI or CT scans may show characteristic abnormalities such as edema or mass lesions 1.
Viral PCR Testing: Essential for identifying specific pathogens in CSF or brain tissue 1.
Serological Tests: Useful for detecting antibodies against suspected pathogens 1.Management
Antiviral Therapy: Initiate based on suspected pathogen (e.g., acyclovir for herpes simplex encephalitis) 1.
Supportive Care: Includes management of intracranial pressure, seizures, and systemic infection 1.
Anticonvulsants: For seizure control, typically levetiracetam or phenytoin 1.
Corticosteroids: Considered in certain cases to reduce inflammation, though evidence varies 1.
Reversal of Anticoagulation: In anticoagulated patients requiring emergency procedures like lumbar puncture, use idarucizumab to reverse dabigatran effects 1.Special Populations
Pregnancy: Management focuses on balancing maternal and fetal safety; specific antiviral dosing may differ 1.
Pediatrics: Close monitoring and tailored antiviral dosing based on weight are crucial 1.
Elderly: Increased vigilance for complications and individualized supportive care 1.
Comorbidities: Consider additional risks and tailor treatment plans accordingly, especially regarding anticoagulation management 1.Key Recommendations
Perform emergency lumbar puncture in suspected infective encephalitis cases on dabigatran after reversing anticoagulation with idarucizumab to avoid hemorrhagic complications (Evidence: Expert opinion) 1.
Initiate empirical antiviral therapy promptly based on clinical suspicion and local epidemiology (Evidence: Moderate) 1.
Use supportive measures including anticonvulsants and intracranial pressure management tailored to individual patient needs (Evidence: Moderate) 1.References
1 Braemswig TB, Eschenfelder CC, Nolte CH. Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab. The American journal of emergency medicine 2017. link